HJ-004-02

N/A

Report date: 2025/09/25 16:24:19
NME

Base Information

Drug NameHJ-004-02
Drug Alias NameHJ-004-02HJ00402
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulators
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJing Medicine Technology (Shanghai) Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTongji UniversityJing Medicine Technology (Shanghai) Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A